A weekly summary of Novamind news and media, including the announcement of Novamind’s application for trading on the OTCQB in the United States.
OPINION July 20, 2021
Shadow Work, Unconscious Contracts, & Unearned Wisdom
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer explore several aspects of the unconscious mind.
Visit us at psychedelictherapyfrontiers.com to learn more, subscribe and catch up on previous episodes you may have missed.
FEATURES July 20, 2021
The Right Approach to Ketamine Therapy
Chief Medical Officer Dr. Reid Robison explains the three pillars of Ketamine therapy and the steps we take to prevent misuse.
“I’ve never had a client who we’ve done the appropriate process with who has entered into a troubled relationship with ketamine through the course of their treatment.”
FEATURES July 22, 2021
Dr. Reid Robison on the New Era of Mental Health
Our Chief Medical Officer joins Health Professional Radio to discuss psychedelic medicine and our rapid expansion phase as we grow our network of clinics, research sites and therapeutic retreats specialized in psychedelic medicine.
“We’re expanding even more with the need that has come up through the pandemic and the willingness to look towards new and improved ways of approaching our mental health”
Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States
We are pleased to announce that we have submitted our application to have our common shares posted for trading on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“Having the Company’s common shares posted for trading on the OTCQB and providing a more efficient way of trading our shares will be an important milestone in our strategy of building awareness and enhancing accessibility amongst United States investors looking for exposure to the growth potential of Novamind’s mental health and psychedelic medicine business,” said Yaron Conforti, CEO and Director of Novamind.
July 21, 2021
A groundbreaking Yale study has uncovered a new dimension in understanding how psychedelics affect us: with small, physical changes to the brain. The study tracked how psilocybin, the active molecule in psychedelic mushrooms, not only has significant and long-lasting effects on mood but actually stimulates growth of new neuronal connections within the brain.
Governments around the world accelerated the clinical research process to develop vaccines for the Covid-19 health crisis. So why can’t we do the same for drugs to treat the mental health crisis? Monnica Williams and Morgan Campbell argue the point in the Baltimore Sun, comparing the investment in mental health treatment with physical health treatment: Investment in psychiatric therapies has remained very low compared to the burden of diseases, with $1.80 per $1,000 in disease burden for major depression and $0.40 for bipolar disorder compared to $9.40 for COPD, $7.60 for diabetes and $75.50 for cancer.
Doctors treating depression see promise in ketamine, a cheap drug already approved for anesthesia
The popularity of using ketamine as a psychedelic treatment is only growing, according to ABC News. Less than 60 ketamine clinics existed in the United States in 2015. In 2018, that number climbed to over 300. With over 7,000 ketamine treatments to date, Novamind remains one of the busiest and most experienced ketamine practices in America.
Michael Pollan’s Adventures with Opium, Caffeine and Mescaline
Michael Pollan, the award-winning journalist who wrote “How to Change Your Mind,” a comprehensive examination of psychedelics history and his personal experience, is back. His new book contrasts the effects of three plant-based substances: caffeine, opium and mescaline. His section on mescaline further destigmatizes psychedelics through a critical and journalistic lens.
Follow @novamind_inc on Instagram
For further information, contact:
Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., ketamine, MDMA